Abstract
Free full text
Recurrent positive SARS‐CoV‐2: Immune certificate may not be valid
To the Editor,
Currently, coronavirus disease in 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) 1 has become a global pandemic. The presence of SARS‐CoV‐2 in patients with COVID‐19 is usually confirmed using real‐time reverse‐transcriptase polymerase chain reaction (RT‐PCR) method. 2 Our hospital previously reported four cases of recurrent positive RT‐PCR test results in healthcare providers recovered from COVID‐19. 3 It is still unknown to what extend this problem occurs and why it happens. Many also believe that people who have had COVID‐19 and been tested positive for immunoglobulin G (IgG) antibodies for SARS‐CoV‐2 may show that as an immune certificate and return to normal life. We assessed the rate of recurrent positive RT‐PCR test results for SARS‐CoV‐2 in patients who were recovering from COVID‐19 and the results of their immunoglobulin M (IgM)/IgG tests 4 for SARS‐CoV‐2.
We used data from 150 patients who were recovering from COVID‐19 and received RT‐PCR tests and IgM/IgG rapid tests for SARS‐CoV‐2 in Zhongnan Hospital of Wuhan University in Wuhan, China from 1 March 2020 to 13 March 2020. Patients who were recovering from COVID‐19 had two consecutively negative RT‐PCR test results separated by at least 24hours. Methods for RT‐PCR test for SARS‐CoV‐2 in throat swabs and serum IgM/IgG rapid test were previously described. 3 , 5 Serum IgM and IgG antibodies to SARS‐CoV‐2 were measured with COVID‐19 IgM/IgG chemiluminescence test kit on a fully‐automated chemiluminescence immunoassay analyzer. The test kit contained recombinant SARS‐CoV‐2 antigen (spike protein and nucleocapsid protein) labeled with magnetic beads, anti‐human IgM monoclonal antibody, and anti‐human IgG monoclonal antibody. Data were collected from electronic medical records. The study was approved by the institutional ethics board at Zhongnan Hospital. Requirement for written informed consent was waived.
Age and days from symptom onset to test were reported as median and interquartile range and differences were compared using Mann‐Whitney test. Categorical variables were described as frequency rates and percentages. The χ 2 test was used for the comparison of categorical variables and Fisher's exact test was used when frequency was too low. Statistical analyses were conducted using SAS software version 9.4 (SAS Institute; Carey, NC). A two‐sided P<.05 was considered statistically significant.
Among 150 patients who were recovering from COVID‐19, 11 (7.3%, 95% confidence interval: 3.1%‐11.6%) tested positive again for SARS‐CoV‐2 in throat swabs. Positive rates for SARS‐CoV‐2 did not differ by sex or age. Characteristics were similar between those positive and those not (Table 1). There were no differences in the prevalence of IgM or IgG to SARS‐CoV‐2 (Figure S1) or serum levels of these antibodies (Table 1) between those positive and those not. All those with recurrent positive SARS‐CoV‐2 were tested positive for IgG to this virus.
Table 1
Median (interquartile range) or n (%) | ||
---|---|---|
Recurrent positive a | Not positive b | |
(n=11) | (n=139) | |
Median age, y | 49 (37‐62) | 54 (40‐63) |
Sex | ||
Female | 5 (45.5) | 71 (51.1) |
Male | 6 (54.5) | 68 (48.9) |
Presence of IgM/IgG to SARS‐CoV‐2 c | ||
IgM | 5 (45.5) | 66 (47.5) |
IgG | 11 (100.0) | 126 (90.6) |
Serum levels of IgM/IgG to SARS‐CoV‐2, AU/mL | ||
IgM | 9.6 (4.1‐24.9) | 8.9 (4.3‐21.9) |
IgG | 243.0 (164.9‐353.1) | 185.1 (76.0‐331.8) |
Days from symptom onset to RT‐PCR test | 38 (35‐44) | 39 (34‐45) |
Days from symptom onset to IgM/IgG test | 39 (37‐46) | 39 (34‐45) |
Note: P values for differences in characteristics between those with recurrent RT‐PCR test results for SARS‐CoV‐2 and those without were all >.05.
Abbreviations: COVID‐19, coronavirus disease‐2019; IgG, immunoglobulin G; IgM, immunoglobulin M; RT‐PCR, reverse‐transcriptase polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
Recurrent positive RT‐PCR tests for SARS‐CoV‐2 were found in 7.3% of patients who were recovering from COVID‐19, indicating that this is a quite common problem. Presence of IgM to SARS‐CoV‐2 was similar between those with recurrent positive RT‐PCR test results and those without, which strongly suggest that it is unlikely due to reinfections with SARS‐CoV‐2 viruses. Those patients with recurrent positive SARS‐CoV‐2 most likely never fully cleared the virus from their systems. Whether they will eventually eradicate the virus is to be studied. The possibility of chronic infection with SARS‐CoV‐2 could not be ruled out and should be closely monitored. Actually, it reported that over 30 cases of patients infected with SARS‐CoV‐2 were never able to clear the virus and were still positive for the virus 2 to 3 months after initial infection, according to the National Health Commission, China. SARS‐CoV‐2 virus was detected in the throat swabs, which strongly suggests that those patients can still shed SARS‐CoV‐2 virus 6 and are infectious. Additionally, those patients all had IgG antibodies to SARS‐CoV‐2, which casts doubts on the protective role of IgG antibodies against this virus and the validity of using positive IgG test results as an immune certificate for COVID‐19. Our findings suggest that some of those with positive IgG test results may be tested positive again for SARS‐CoV‐2 in their throat swabs and thus infectious after two consecutive negative tests for SARS‐CoV‐2. These findings have important implications for public health and management of recovered patients with COVID‐19 around the world.
AUTHOR CONTRIBUTIONS
XW had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. TL, SW, and GZ contributed equally to the study. XW, FG, and YL contributed equally as senior authors. Concept and design: TL, SW, and GZ. Acquisition, analysis, or interpretation of data: TL, SW, GZ, and FZ. Drafting of the manuscript: TL, SW, FG, and XW. Critical revision of the manuscript for important intellectual content: SW and XW. Statistical analysis: TL and FG.
ACKNOWLEDGMENTS
The part of the study was supported by National Key Research and Development Program of China (2020YFC0845500). The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.
Notes
Funding Information National Key Research and Development Program of China, Grant/Award Number: 2020YFC0845500
Tao Liu, Sanyun Wu, and Guang Zeng contributed equally as first authors to this work. Yirong Li, Fangjian Guo, and Xinghuan Wang contributed equally as senior authors to this work.
Contributor Information
Fangjian Guo, Email: ude.bmtu@ougaf.
Xinghuan Wang, Email: nc.ude.uhw@nauhgnixgnaw.
REFERENCES
Full text links
Read article at publisher's site: https://doi.org/10.1002/jmv.26074
Read article for free, from open access legal sources, via Unpaywall: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jmv.26074
Citations & impact
Impact metrics
Citations of article over time
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1002/jmv.26074
Article citations
Metabolic Syndrome Is Associated with Poor Omicron Infection Prognosis While Inactivated Vaccine Improves the Outcome of Coronavirus Disease 2019 among Chinese Inhabitants: A Retrospective Observational Study from a Chinese Municipality.
Vaccines (Basel), 11(10):1554, 30 Sep 2023
Cited by: 0 articles | PMID: 37896957 | PMCID: PMC10611402
Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis.
BMC Public Health, 23(1):778, 28 Apr 2023
Cited by: 4 articles | PMID: 37118717 | PMCID: PMC10140730
Review Free full text in Europe PMC
Recurrent SARS-CoV-2 infections and their potential risk to public health - a systematic review.
PLoS One, 16(12):e0261221, 09 Dec 2021
Cited by: 6 articles | PMID: 34882750 | PMCID: PMC8659325
Review Free full text in Europe PMC
The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.
Pathog Glob Health, 116(5):269-281, 31 Jan 2022
Cited by: 18 articles | PMID: 35099367 | PMCID: PMC9248963
Review Free full text in Europe PMC
Recurrence, Reactivation, or Inflammatory Rebound of SARS-CoV-2 Infection With Acute Vestibular Symptoms: A Case Report and Revision of Literature.
Front Hum Neurosci, 15:666468, 11 Aug 2021
Cited by: 7 articles | PMID: 34456694 | PMCID: PMC8385757
Go to all (15) article citations
Data
Data behind the article
This data has been text mined from the article, or deposited into data resources.
BioStudies: supplemental material and supporting data
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.
Kidney Int, 99(2):486-488, 01 Feb 2021
Cited by: 23 articles | PMID: 33509358 | PMCID: PMC7830266
Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response.
J Immunol Methods, 496:113096, 06 Jul 2021
Cited by: 10 articles | PMID: 34242653 | PMCID: PMC8259047
Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
J Med Virol, 93(5):2857-2866, 01 Mar 2021
Cited by: 19 articles | PMID: 33331654
Serological tests for COVID-19: Potential opportunities.
Cell Biol Int, 45(4):740-748, 13 Jan 2021
Cited by: 16 articles | PMID: 33289157 | PMCID: PMC7753382
Review Free full text in Europe PMC
A comparative review of immunoassays for COVID-19 detection.
Expert Rev Clin Immunol, 17(6):573-599, 01 Jun 2021
Cited by: 54 articles | PMID: 33787412
Review
Funding
Funders who supported this work.
National Key Research and Development Program of China (1)
Grant ID: 2020YFC0845500